HUM vs RXRX
Humana Inc (HUM) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported HUM revenue for 2024-12-31 was $117.76B. Net income was $1.21B. Revenue was up 10.7% from 2023-12-31 to 2024-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the HUM and RXRX stock pages for the full models.
Not investment advice.